76
|
Noguchi S, Kumazaki M, Mori T, Baba K, Okuda M, Mizuno T, Akao Y. Cover Image, Volume 14, Issue 4. Vet Comp Oncol 2016. [DOI: 10.1111/vco.12283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
77
|
Mizuno T, Umemura Y. Dynamic Stretching does not Change the Stiffness of the Muscle-Tendon Unit. Int J Sports Med 2016; 37:e12. [PMID: 27737485 DOI: 10.1055/s-0042-118268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
78
|
Konno T, Yoshida K, Mizuno T, Kawarai T, Tada M, Nozaki H, Ikeda SI, Nishizawa M, Onodera O, Wszolek ZK, Ikeuchi T. Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation. Eur J Neurol 2016; 24:37-45. [PMID: 27680516 PMCID: PMC5215554 DOI: 10.1111/ene.13125] [Citation(s) in RCA: 99] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Accepted: 08/09/2016] [Indexed: 01/13/2023]
Abstract
Background and purpose The clinical characteristics of colony stimulating factor 1 receptor (CSF1R) related adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) have been only partially elucidated. Methods Clinical data from CSF1R mutation carriers who had been seen at our institutions or reported elsewhere were collected and analysed using a specific investigation sheet to standardize the data. Results In all, 122 cases from 90 families with CSF1R mutations were identified. The mean age of onset was 43 years (range 18–78 years), the mean age at death was 53 years (range 23–84 years) and the mean disease duration was 6.8 years (range 1–29 years). Women had a significantly younger age of onset than men (40 vs. 47 years, P = 0.0006, 95% confidence interval 3.158–11.177). There was an age‐dependent penetrance that was significantly different between the sexes (P = 0.0013). Motor dysfunctions were the most frequent initial symptom in women whose diseases began in their 20s. Thinning of the corpus callosum, abnormal signalling in pyramidal tracts, diffusion‐restricted lesions and calcifications in the white matter were characteristic imaging findings of ALSP. The calcifications were more frequently reported in our case series than in the literature (54% vs. 3%). Seventy‐nine per cent of the mutations were located in the distal part of the tyrosine kinase domain of CSF1R (102 cases). There were no apparent phenotype−genotype correlations. Conclusions The characteristics of ALSP were clarified. The phenotype of ALSP caused by CSF1R mutations is affected by sex.
Collapse
|
79
|
Mizuno T, Umemura Y. Dynamic Stretching does not Change the Stiffness of the Muscle-Tendon Unit. Int J Sports Med 2016; 37:1044-1050. [PMID: 27676152 DOI: 10.1055/s-0042-108807] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
The purpose of this study was to identify changes in ankle range of motion and passive mechanical properties of the muscle-tendon unit after dynamic stretching. 12 healthy subjects participated in this study. Displacement of the muscle-tendon junction was measured using ultrasonography while the ankle was passively dorsiflexed at 1°/sec to its maximal dorsiflexion angle. Passive torque was also measured using an isokinetic dynamometer. Measurements were conducted pre-intervention, immediately after the intervention and 5, 10, 15 and 30 min post-intervention. The dynamic stretching consisted of four 30-s periods of ankle dorsiflexion and plantarflexion. Ankle range of motion was significantly increased immediately (from 18.3±1.8° to 21.4±1.7°) and 10 min (20.9±1.9°) after dynamic stretching, but this change disappeared within 15 min. However, stiffness of the muscle-tendon unit and displacement of the muscle-tendon junction at the submaximal dorsiflexion angle did not differ between the experimental conditions. These results demonstrate that dynamic stretching by contracting an antagonist muscle group increases ankle range of motion temporarily without changing the passive mechanical properties of the muscle-tendon unit. The increased range of motion of the ankle after dynamic stretching might be caused by enhanced stretch tolerance.
Collapse
|
80
|
Ashida R, Okamura Y, Nakao K, Mizuno T, Aoki S, Kiuchi R, Sugiura T, Ito T, Yamamoto Y, Mochizuki T, Uesaka K. MON-P241: The Impact of Preoperative Enteral Nutrition Enriched Administration with Eicosapentaenoic Acid (EPA) on Postoperative Hypercytokinemia after Pancreatoduodenectomy: Results of a Double-Blinded Randomized Controlled Trial. Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30875-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
81
|
Emoto C, Fukuda T, Mizuno T, Schniedewind B, Christians U, Adams DM, Vinks AA. Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY 2016; 5:411-7. [PMID: 27501453 PMCID: PMC4999604 DOI: 10.1002/psp4.12096] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Revised: 06/07/2016] [Accepted: 06/21/2016] [Indexed: 01/25/2023]
Abstract
Sirolimus is increasingly being used in neonates and infants, but the mechanistic basis of age‐dependent changes in sirolimus disposition has not been fully addressed yet. In order to characterize the age‐dependent changes, serial sirolimus clearance (CL) estimates in individual young pediatric patients were collected and analyzed by population modeling analysis. In addition, sirolimus metabolite formation was also investigated to further substantiate the corresponding age‐dependent change in CYP3A activity. The increasing pattern over time of allometrically size‐normalized sirolimus CL estimates vs. age was well described by a sigmoidal Emax model. This age‐dependent increase was also observed within each individual patient over a 4‐year study period. CYP3A‐dependent sirolimus metabolite formation changed in a similar fashion. This study clearly demonstrates the rapid increase of sirolimus CL over time in neonates and infants, indicating the developmental change. This developmental pattern can be explained by a parallel increase in CYP3A metabolic activity.
Collapse
|
82
|
Hayashi N, Takada Y, Mizuno T, Nakae H, Murai T. SU-F-T-255: Accuracy and Precision of Dynamic Tracking Irradiation with VERO-4DRT System. Med Phys 2016. [DOI: 10.1118/1.4956395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
83
|
Nakamura Y, Suzuki R, Mizuno T, Abe K, Chiba S, Horii Y, Tsuboi J, Ito S, Obara W, Tanita T, Kanno H, Yamauchi K. Therapeutic implication of genetic variants of IL13 and STAT4 in airway remodelling with bronchial asthma. Clin Exp Allergy 2016; 46:1152-61. [PMID: 26765219 DOI: 10.1111/cea.12710] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Revised: 12/31/2015] [Accepted: 01/05/2016] [Indexed: 02/01/2023]
Abstract
BACKGROUND Several gene variants identified in bronchial asthmatic patients are associated with a decrease in pulmonary function. The effects of this intervention on pulmonary function have not been fully researched. OBJECTIVE We determined the effects of high-dose inhaled corticosteroids (ICSs) on decreased pulmonary function in asthmatic Japanese patients with variants of IL13 and STAT4 during long-term treatments with low to mild doses of ICS. METHODS In this study, 411 patients with bronchial asthma who were receiving ICSs and living in Japan were recruited, were genotyped, and underwent pulmonary function tests and fibreoptic examinations. The effects of 2 years of high-dose ICSs administered to asthmatic patients who were homozygous for IL13 AA of rs20541 or STAT4 TT of rs925847 and who progressed to airway remodelling were investigated. RESULTS High-dose ICS treatment increased the pulmonary function of patients homozygous for IL13 AA of rs20541 but not of patients homozygous for STAT4 TT of rs925847. The increased concentrations of the mediators IL23, IL11, GMCSF, hyaluronic acid, IL24, and CCL8 in bronchial lavage fluid (BLF) were diminished after high-dose ICS treatment in patients homozygous for IL13 AA of rs20541. CONCLUSION AND CLINICAL RELEVANCE IL13 AA of rs20541 and STAT4 TT of rs925847 are potential genomic biomarkers for predicting lower pulmonary function. The administration of high-dose ICSs to asthmatic patients with genetic variants of IL13 AA may inhibit the advancement of airway remodelling. The genetic variants of STAT4 TT did not respond to high-dose ICSs. Therefore, using medications other than ICSs must be considered even during the initial treatment of bronchial asthma. These genetic variants may aid in the realization of personalized and phenotype-specific therapies for bronchial asthma.
Collapse
|
84
|
Ajello M, Albert A, Anderson B, Baldini L, Barbiellini G, Bastieri D, Bellazzini R, Bissaldi E, Blandford RD, Bloom ED, Bonino R, Bottacini E, Bregeon J, Bruel P, Buehler R, Caliandro GA, Cameron RA, Caragiulo M, Caraveo PA, Cecchi C, Chekhtman A, Ciprini S, Cohen-Tanugi J, Conrad J, Costanza F, D'Ammando F, de Angelis A, de Palma F, Desiante R, Di Mauro M, Di Venere L, Domínguez A, Drell PS, Favuzzi C, Focke WB, Franckowiak A, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Giglietto N, Glanzman T, Godfrey G, Guiriec S, Horan D, Jóhannesson G, Katsuragawa M, Kensei S, Kuss M, Larsson S, Latronico L, Li J, Li L, Longo F, Loparco F, Lubrano P, Madejski GM, Maldera S, Manfreda A, Mayer M, Mazziotta MN, Meyer M, Michelson PF, Mirabal N, Mizuno T, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Negro M, Nuss E, Okada C, Orlando E, Ormes JF, Paneque D, Perkins JS, Pesce-Rollins M, Piron F, Pivato G, Porter TA, Rainò S, Rando R, Razzano M, Reimer A, Sánchez-Conde M, Sgrò C, Simone D, Siskind EJ, Spada F, Spandre G, Spinelli P, Takahashi H, Thayer JB, Torres DF, Tosti G, Troja E, Uchiyama Y, Wood KS, Wood M, Zaharijas G, Zimmer S. Search for Spectral Irregularities due to Photon-Axionlike-Particle Oscillations with the Fermi Large Area Telescope. PHYSICAL REVIEW LETTERS 2016; 116:161101. [PMID: 27152783 DOI: 10.1103/physrevlett.116.161101] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/27/2015] [Indexed: 06/05/2023]
Abstract
We report on the search for spectral irregularities induced by oscillations between photons and axionlike-particles (ALPs) in the γ-ray spectrum of NGC 1275, the central galaxy of the Perseus cluster. Using 6 years of Fermi Large Area Telescope data, we find no evidence for ALPs and exclude couplings above 5×10^{-12} GeV^{-1} for ALP masses 0.5≲m_{a}≲5 neV at 95% confidence. The limits are competitive with the sensitivity of planned laboratory experiments, and, together with other bounds, strongly constrain the possibility that ALPs can reduce the γ-ray opacity of the Universe.
Collapse
|
85
|
Mizuno T, Iwata T. Hadamard-transform fluorescence-lifetime imaging. OPTICS EXPRESS 2016; 24:8202-8213. [PMID: 27137259 DOI: 10.1364/oe.24.008202] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
We discuss a Hadamard-transform-based fluorescence-lifetime-imaging (HT-FLI) technique for fluorescence-lifetime-imaging microscopy (FLIM). The HT-FLI uses a Fourier-transform phase-modulation fluorometer (FT-PMF) for fluorescence-lifetime measurements, where the modulation frequency of the excitation light is swept linearly in frequency from zero to a specific maximum during a fixed duration of time. Thereafter, fluorescence lifetimes are derived through Fourier transforms for the fluorescence and reference waveforms. The FT-PMF enables the analysis of multi-component samples simultaneously. HT imaging uses electronic exchange of HT illumination mask patterns, and a high-speed, high-sensitivity photomultiplier, to eliminate frame-rate issues that accompany two-dimensional image detectors.
Collapse
|
86
|
Ackermann M, Ajello M, Albert A, Atwood WB, Baldini L, Ballet J, Barbiellini G, Bastieri D, Bechtol K, Bellazzini R, Bissaldi E, Blandford RD, Bloom ED, Bonino R, Bregeon J, Britto RJ, Bruel P, Buehler R, Caliandro GA, Cameron RA, Caragiulo M, Caraveo PA, Cavazzuti E, Cecchi C, Charles E, Chekhtman A, Chiang J, Chiaro G, Ciprini S, Cohen-Tanugi J, Cominsky LR, Costanza F, Cutini S, D'Ammando F, de Angelis A, de Palma F, Desiante R, Digel SW, Di Mauro M, Di Venere L, Domínguez A, Drell PS, Favuzzi C, Fegan SJ, Ferrara EC, Franckowiak A, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Giglietto N, Giommi P, Giordano F, Giroletti M, Godfrey G, Green D, Grenier IA, Guiriec S, Hays E, Horan D, Iafrate G, Jogler T, Jóhannesson G, Kuss M, La Mura G, Larsson S, Latronico L, Li J, Li L, Longo F, Loparco F, Lott B, Lovellette MN, Lubrano P, Madejski GM, Magill J, Maldera S, Manfreda A, Mayer M, Mazziotta MN, Michelson PF, Mitthumsiri W, Mizuno T, Moiseev AA, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Negro M, Nuss E, Ohsugi T, Okada C, Omodei N, Orlando E, Ormes JF, Paneque D, Perkins JS, Pesce-Rollins M, Petrosian V, Piron F, Pivato G, Porter TA, Rainò S, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Reposeur T, Romani RW, Sánchez-Conde M, Schmid J, Schulz A, Sgrò C, Simone D, Siskind EJ, Spada F, Spandre G, Spinelli P, Suson DJ, Takahashi H, Thayer JB, Tibaldo L, Torres DF, Troja E, Vianello G, Yassine M, Zimmer S. Resolving the Extragalactic γ-Ray Background above 50 GeV with the Fermi Large Area Telescope. PHYSICAL REVIEW LETTERS 2016; 116:151105. [PMID: 27127954 DOI: 10.1103/physrevlett.116.151105] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2015] [Indexed: 05/16/2023]
Abstract
The Fermi Large Area Telescope (LAT) Collaboration has recently released a catalog of 360 sources detected above 50 GeV (2FHL). This catalog was obtained using 80 months of data re-processed with Pass 8, the newest event-level analysis, which significantly improves the acceptance and angular resolution of the instrument. Most of the 2FHL sources at high Galactic latitude are blazars. Using detailed Monte Carlo simulations, we measure, for the first time, the source count distribution, dN/dS, of extragalactic γ-ray sources at E>50 GeV and find that it is compatible with a Euclidean distribution down to the lowest measured source flux in the 2FHL (∼8×10^{-12} ph cm^{-2} s^{-1}). We employ a one-point photon fluctuation analysis to constrain the behavior of dN/dS below the source detection threshold. Overall, the source count distribution is constrained over three decades in flux and found compatible with a broken power law with a break flux, S_{b}, in the range [8×10^{-12},1.5×10^{-11}] ph cm^{-2} s^{-1} and power-law indices below and above the break of α_{2}∈[1.60,1.75] and α_{1}=2.49±0.12, respectively. Integration of dN/dS shows that point sources account for at least 86_{-14}^{+16}% of the total extragalactic γ-ray background. The simple form of the derived source count distribution is consistent with a single population (i.e., blazars) dominating the source counts to the minimum flux explored by this analysis. We estimate the density of sources detectable in blind surveys that will be performed in the coming years by the Cherenkov Telescope Array.
Collapse
|
87
|
Suda S, Okubo S, Ueda M, Sowa K, Abe A, Aoki J, Muraga K, Suzuki K, Sakamoto Y, Mizuta I, Mizuno T, Kimura K. A Japanese CADASIL kindred with a novel two-baseNOTCH3mutation. Eur J Neurol 2016; 23:e32-4. [DOI: 10.1111/ene.12977] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Accepted: 01/18/2016] [Indexed: 11/29/2022]
|
88
|
Ackermann M, Ajello M, Albert A, Atwood WB, Baldini L, Barbiellini G, Bastieri D, Bellazzini R, Bissaldi E, Blandford RD, Bonino R, Bottacini E, Bregeon J, Bruel P, Buehler R, Caliandro GA, Cameron RA, Caragiulo M, Caraveo PA, Cavazzuti E, Cecchi C, Chekhtman A, Chiang J, Chiaro G, Ciprini S, Claus R, Cohen-Tanugi J, Costanza F, Cuoco A, Cutini S, D’Ammando F, de Angelis A, de Palma F, Desiante R, Digel SW, Di Venere L, Drell PS, Favuzzi C, Fegan SJ, Focke WB, Franckowiak A, Funk S, Fusco P, Gargano F, Gasparrini D, Giglietto N, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Grove JE, Guiriec S, Harding AK, Hewitt JW, Horan D, Hou X, Iafrate G, Jóhannesson G, Kamae T, Kuss M, Larsson S, Latronico L, Li J, Li L, Longo F, Loparco F, Lovellette MN, Lubrano P, Magill J, Maldera S, Manfreda A, Mayer M, Mazziotta MN, Michelson PF, Mitthumsiri W, Mizuno T, Monzani ME, Morselli A, Murgia S, Nuss E, Omodei N, Orlando E, Ormes JF, Paneque D, Perkins JS, Pesce-Rollins M, Petrosian V, Piron F, Pivato G, Rainò S, Rando R, Razzano M, Reimer A, Reimer O, Reposeur T, Sgrò C, Siskind EJ, Spada F, Spandre G, Spinelli P, Takahashi H, Thayer JB, Thompson DJ, Tibaldo L, Torres DF, Tosti G, Troja E, Vianello G, Winer BL, Wood KS, Yassine M, Cerutti F, Ferrari A, Sala PR. Measurement of the high-energy gamma-ray emission from the Moon with the Fermi Large Area Telescope. PHYSICAL REVIEW. D. (2016) 2016; 93:082001. [PMID: 32743154 PMCID: PMC7394319 DOI: 10.1103/physrevd.93.082001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
We have measured the gamma-ray emission spectrum of the Moon using the data collected by the Large Area Telescope onboard the Fermi satellite during its first seven years of operation, in the energy range from 30 MeV up to a few GeV. We have also studied the time evolution of the flux, finding a correlation with the solar activity. We have developed a full Monte Carlo simulation describing the interactions of cosmic rays with the lunar surface. The results of the present analysis can be explained in the framework of this model, where the production of gamma rays is due to the interactions of cosmic-ray proton and helium nuclei with the surface of the Moon. Finally, we have used our simulation to derive the cosmic-ray proton and helium spectra near Earth from the Moon gamma-ray data.
Collapse
|
89
|
Sagara Y, Sawaki M, Taira N, Saito T, Kashiwaba M, Iwata H, Kobayashi K, Nakayama T, Bando H, Mizuno T, Yamamoto Y, Tsuneizumi M, Takahashi M, Yamaguchi M, Kawashima H, Takashima T, Uemura Y, Hozumi Y, Sagawa N, Mukai H, Ohashi Y. Abstract P5-18-01: A randomized clinical trial of postoperative adjuvant therapy for elderly breast cancer patients: Conditions of obtaining informed consent and reasons for declining participation. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-18-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: There are few randomized clinical trials examining adjuvant treatment in elderly breast cancer patients. While obtaining informed consent is essential for participation in clinical studies, there is little information on the frequency of agreement to participate among elderly patients. Furthermore, elderly patients might have specific reasons to decline participation.
Patients and Method: The National Surgical Adjuvant Study of Breast Cancer 07 (N-SAS BC 07) is a randomized clinical trial in women over 70 years with HER2-positive primary breast cancer. The primary aim was to investigate the benefit of trastuzumab monotherapy compared with the combination of trastuzumab and chemotherapy. Key inclusion criteria were as follows: women between 70 and 80 years old with HER2-positive breast cancer; underwent curative operation; stage I to IIIA; with sufficient organ function. Patients were randomized to receive either trastuzumab plus chemotherapy or trastuzumab monotherapy. The primary endpoint was disease-free survival, and the secondary endpoints were overall survival, relapse-free survival, safety, health-related quality of life, and cost effectiveness (NCT01104935). It was not possible to predict the number of patients who would agree to participate. In order to comprehensively assess the effect of postoperative adjuvant therapy, we evaluated the reasons why eligible patients declined to participate. The patients were registered in a cohort study to prospectively evaluate the subsequent treatment options and prognosis (07-Cohort). This study examined the obtaining of informed consent for N-SAS BC 07 and the reasons for declining participation, and compared the clinicopathological backgrounds between the N-SAS BC 07 and 07-Cohort groups.
Results: 398 eligible patients have been recruited. Informed consent to participate in N-SAS BC 07 has been obtained from 275 patients (69%) and 123 patients (31%) who declined to participate in the RCT have been registered in the 07-Cohort. The common reasons to decline participation in the RCT were "cannot choose the treatment option (55%)", "refused chemotherapy (16%)", "wanted chemotherapy (9%)", "anxious about clinical studies (9%)" and "family opposition (8%)". The mean ages of the patients in N-SAS BC 07 and 07-Cohort were 73.9 and 74.6 years old, respectively. There were no differences in stage, surgical procedure, lymph node metastasis, or co-morbidities between the groups. ER-positive rate was higher in 07-Cohort group compared with N-SAS BC 07 group (53% vs. 37%, p=0.017, χ2 test).
Conclusion: While we expected the number of registrants to be small, since N-SAS BC 07 investigated whether elderly patients with HER2-positive breast cancer should undergo chemotherapy, almost 70% of the patients accepted informed consent. The most common reason to decline participation in N-SAS BC 07 was "cannot choose the treatment option" and the majority refused chemotherapy. Furthermore, ER-positivity was higher in the 07-Cohort group, which suggested that ER expression in the patients with HER2-positive breast cancer might influence their decision to participate in the study or to choose the treatment option.
Citation Format: Sagara Y, Sawaki M, Taira N, Saito T, Kashiwaba M, Iwata H, Kobayashi K, Nakayama T, Bando H, Mizuno T, Yamamoto Y, Tsuneizumi M, Takahashi M, Yamaguchi M, Kawashima H, Takashima T, Uemura Y, Hozumi Y, Sagawa N, Mukai H, Ohashi Y. A randomized clinical trial of postoperative adjuvant therapy for elderly breast cancer patients: Conditions of obtaining informed consent and reasons for declining participation. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-18-01.
Collapse
|
90
|
Ishihara M, Tamaru S, Oda H, Yamashita Y, Tono Y, Mizuno T, Katayama N. Abstract P4-13-21: A pilot study of pertuzumab, trastuzumab and eribulin for patients with advanced HER2 positive breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-13-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Introduction] The triple therapy of pertuzumab, trastuzumab and taxanes (docetaxel or paclitaxel) is coming into widespread use, because of the beneficial effects on HER2 positive breast cancer. However, we don't have enough information about the efficacy and safety of other agents with trastuzumab and pertuzumab (TP). We studied triple therapy of pertuzumab, trastuzumab and eribulin (PTE) for advanced HER2 positive breast cancer to assess the efficacy, safety and QOL prospectively (UMIN000012018).
[Patients and methods] Responses were assessed by RECIST criteria v1.1. Adverse events (AEs) were graded according to CTCAE v4.0. Patients with advanced HER2 positive breast cancer were treated with pertuzumab (840 mg loading then 420 mg, day 1), trastuzumab (8 mg/kg loading then 6 mg/kg, day 1), and eribulin (1.4 mg/m2, day 1 and 8) every 3 weeks. Dose reduction was allowed when patients developed febrile neutropenia, grade 3-5 non-hematologic toxicity or skipped day 8 eribulin administration because of neutrophil count <1000/mm3. QOL was assessed using FACT-B at baseline and 3 months after initial treatment.
[Results] Ten patients were enrolled. Median age of patients was 60 years-old (35-75). Median number of prior chemoregimen for metastatic disease was 3 (0-5). Two patients had a history of docetaxel allergy. Median number of PTE cycle was 6 (3-12). Eight patients reduced eribulin doses 1.4 mg/m2 to 1.1 mg/m2 because of AEs (2 patients), skipped day 8 eribulin (4 patients), or physician's choice (2 patients). One complete response, 1 partial response and 5 stable disease were achieved at 3 months. Two patients (1 CR and 1 SD) stopped eribulin and received TP as maintenance therapy. At 3 months, all 3 patients with progressive disease developed brain metastasis. Two patients had extracranial progressive lesions, but 1 patient had partial response for extracranial disease.
The common treatment-related AEs were leukopenia, neutropenia, lymphopenia diarrhea, hypokalemia and stomatitis. Grade 3 AEs were leukopenia (7 patients), neutropenia (8 patients), lymphopenia (2 patients), febrile neutropenia (1 patient), hypokalemia (1 patient) and peripheral neuropathy (1 patient). Grade 4/5 AEs were not observed.
Nine patients could be assessed QOL. FACT-B TOI, FACT-G and FACT-B total score had a tendency to be improved at 3 months.
[Conclusion] The PTE therapy showed appropriate clinical effect for extracranial lesions and maintained QOL of patients with advanced HER2 positive breast cancer. It may be a choice for patients who have taxane-resistant diseases or a history of taxane allergy.
Many patients needed to reduce eribulin dosage. When the PTE therapy is referred to advanced HER2 positive breast cancer patients as a palliative chemotherapy, eribulin (1.1mg/m2) might be a reasonable dosage.
Citation Format: Ishihara M, Tamaru S, Oda H, Yamashita Y, Tono Y, Mizuno T, Katayama N. A pilot study of pertuzumab, trastuzumab and eribulin for patients with advanced HER2 positive breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-21.
Collapse
|
91
|
Saito T, Sawaki M, Hozumi Y, Sagawa N, Iwata H, Kashiwaba M, Kawashima H, Kobayashi K, Taira N, Takashima T, Takahashi M, Tsuneizumi M, Nakayama T, Baba S, Bando H, Mizuno T, Yamaguchi M, Yamamoto Y, Uemura Y, Ohashi Y, Mukai H. Abstract P4-11-09: A randomized controlled trial of postoperative adjuvant therapy for elderly breast cancer patients: Comparison of health-related quality of life between clinical trial participants and decliners. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-11-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Health-related quality of life (HRQoL) is one of the important outcomes in cancer control trials and has increasingly become the one of the primary foci. Obtaining informed consent from participants is essential for participation in randomized controlled trials (RCTs), but the participation in these RCTs may directly influence HRQoL, because treatment options are determined according to the allocation schedule. To date, only a few studies have compared HRQoL between clinical trial participants and decliners.
Patients and Method: The National Surgical Adjuvant Study of Breast Cancer 07 (N-SAS BC 07) is a randomized controlled trial in women with HER2-positive primary breast cancer who are over 70 years of age. The primary aim was to investigate the benefit of trastuzumab monotherapy compared with combination therapy using trastuzumab and chemotherapy. The study concept and design were published in concept paper (Sawaki M. et al., Jpn J Clin Oncol. 2011). In this study, patients were randomized to receive either trastuzumab plus chemotherapy or trastuzumab monotherapy. The primary endpoint was disease-free survival, and the secondary endpoints were overall survival, relapse-free survival, safety, HRQoL, comprehensive geriatric assessment (CGA) and cost effectiveness (protocol ID; NCT01104935).
HRQoL and CGA were assessed at registration (baseline), 2 month, 1 year, and 3 years after the start of protocol treatments using the Functional Assessment of Cancer Therapy-General (FACT-G), Hospital Anxiety and Depression Scale (HADS), EuroQol 5 Dimension (EQ-5D), Tokyo Metropolitan Institute of Gerontology (TMIG) index of competence, and the Philadelphia Geriatric Center (PGC) Morale Scale.
The patients who declined to participate in N-SAS BC 07 were registered in a cohort study to prospectively evaluate the subsequent treatment options and prognosis (07-Cohort). The same questionnaire that was used in N-SAS BC 07 was used in 07-Cohort to evaluate HRQoL and CGA at entry.
Results: Patients were enrolled from October 2012 to October 2016. During this period, 275 and 123 patients were registered in N-SAS BC 07 and 07-Cohort, respectively. The mean age at entry of the patients in the N-SAS BC 07 and 07-Cohort groups was 73.9 and 74.6 years, respectively. The questionnaire response rates at baseline in the patients in N-SAS BC 07 and 07-Cohort groups were 89% and 82%, respectively. There were no significant differences in FACT-G, HADS, EQ-5D, or TMIG index of competence at baseline between the groups, but the mean (standard deviation) scores of PGC Morale Scale in N-SAS BC 07 and 07-Cohort groups were 10.8 (3.3) and 9.9 (3.7), respectively, with the scores being significantly greater in the N-SAS BC 07 group (p=0.020, t-test).
Conclusion: The PGC Morale Scale provides a multidimensional approach to assess the psychological state of older people. This study indicated that participation in the RCT did not affect the baseline QoL of elderly patients but suggested that the baseline QoL of the RCT participants was better than decliners.
Citation Format: Saito T, Sawaki M, Hozumi Y, Sagawa N, Iwata H, Kashiwaba M, Kawashima H, Kobayashi K, Taira N, Takashima T, Takahashi M, Tsuneizumi M, Nakayama T, Baba S, Bando H, Mizuno T, Yamaguchi M, Yamamoto Y, Uemura Y, Ohashi Y, Mukai H. A randomized controlled trial of postoperative adjuvant therapy for elderly breast cancer patients: Comparison of health-related quality of life between clinical trial participants and decliners. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-11-09.
Collapse
|
92
|
Chidambaran V, Venkatasubramanian R, Zhang X, Martin LJ, Niu J, Mizuno T, Fukuda T, Meller J, Vinks AA, Sadhasivam S. ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and morphine pharmacokinetics in children. THE PHARMACOGENOMICS JOURNAL 2016; 17:162-169. [PMID: 26810133 PMCID: PMC4959996 DOI: 10.1038/tpj.2015.98] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Revised: 11/04/2015] [Accepted: 11/13/2015] [Indexed: 02/07/2023]
Abstract
Respiratory depression (RD) is a serious side effect of morphine and detrimental to effective analgesia. We reported that variants of the ATP binding cassette gene ABCC3 (facilitates hepatic morphine metabolite efflux) affect morphine metabolite clearance. In this study of 316 children undergoing tonsillectomy, we found significant association between ABCC3 variants and RD leading to prolonged postoperative care unit stay (prolonged RD). Allele A at rs4148412 and allele G at rs729923 caused a 2.36 (95% CI=1.28-4.37, P=0.0061) and 3.7 (95% CI 1.47-9.09, P=0.0050) times increase in odds of prolonged RD, respectively. These clinical associations were supported by increased formation clearance of morphine glucuronides in children with rs4148412 AA and rs4973665 CC genotypes in this cohort, as well as an independent spine surgical cohort of 67 adolescents. This is the first study to report association of ABCC3 variants with opioid-related RD, and morphine metabolite formation (in two independent surgical cohorts).
Collapse
|
93
|
Chauvin M, Florén HG, Jackson M, Kamae T, Kawano T, Kiss M, Kole M, Mikhalev V, Moretti E, Olofsson G, Rydström S, Takahashi H, Iyudin A, Arimoto M, Fukazawa Y, Kataoka J, Kawai N, Mizuno T, Ryde F, Tajima H, Takahashi T, Pearce M. Observation of polarized hard X-ray emission from the Crab by thePoGOLite Pathfinder. ACTA ACUST UNITED AC 2015. [DOI: 10.1093/mnrasl/slv177] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
94
|
Ackermann M, Albert A, Anderson B, Atwood WB, Baldini L, Barbiellini G, Bastieri D, Bechtol K, Bellazzini R, Bissaldi E, Blandford RD, Bloom ED, Bonino R, Bottacini E, Brandt TJ, Bregeon J, Bruel P, Buehler R, Caliandro GA, Cameron RA, Caputo R, Caragiulo M, Caraveo PA, Cecchi C, Charles E, Chekhtman A, Chiang J, Chiaro G, Ciprini S, Claus R, Cohen-Tanugi J, Conrad J, Cuoco A, Cutini S, D'Ammando F, de Angelis A, de Palma F, Desiante R, Digel SW, Di Venere L, Drell PS, Drlica-Wagner A, Essig R, Favuzzi C, Fegan SJ, Ferrara EC, Focke WB, Franckowiak A, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Giglietto N, Giordano F, Giroletti M, Glanzman T, Godfrey G, Gomez-Vargas GA, Grenier IA, Guiriec S, Gustafsson M, Hays E, Hewitt JW, Horan D, Jogler T, Jóhannesson G, Kuss M, Larsson S, Latronico L, Li J, Li L, Llena Garde M, Longo F, Loparco F, Lubrano P, Malyshev D, Mayer M, Mazziotta MN, McEnery JE, Meyer M, Michelson PF, Mizuno T, Moiseev AA, Monzani ME, Morselli A, Murgia S, Nuss E, Ohsugi T, Orienti M, Orlando E, Ormes JF, Paneque D, Perkins JS, Pesce-Rollins M, Piron F, Pivato G, Porter TA, Rainò S, Rando R, Razzano M, Reimer A, Reimer O, Ritz S, Sánchez-Conde M, Schulz A, Sehgal N, Sgrò C, Siskind EJ, Spada F, Spandre G, Spinelli P, Strigari L, Tajima H, Takahashi H, Thayer JB, Tibaldo L, Torres DF, Troja E, Vianello G, Werner M, Winer BL, Wood KS, Wood M, Zaharijas G, Zimmer S. Searching for Dark Matter Annihilation from Milky Way Dwarf Spheroidal Galaxies with Six Years of Fermi Large Area Telescope Data. PHYSICAL REVIEW LETTERS 2015; 115:231301. [PMID: 26684107 DOI: 10.1103/physrevlett.115.231301] [Citation(s) in RCA: 72] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/10/2015] [Indexed: 06/05/2023]
Abstract
The dwarf spheroidal satellite galaxies (dSphs) of the Milky Way are some of the most dark matter (DM) dominated objects known. We report on γ-ray observations of Milky Way dSphs based on six years of Fermi Large Area Telescope data processed with the new Pass8 event-level analysis. None of the dSphs are significantly detected in γ rays, and we present upper limits on the DM annihilation cross section from a combined analysis of 15 dSphs. These constraints are among the strongest and most robust to date and lie below the canonical thermal relic cross section for DM of mass ≲100 GeV annihilating via quark and τ-lepton channels.
Collapse
|
95
|
Kuroda H, Seto K, Yoshida T, Mizuno T, Sakakura N, Hida T, Yatabe Y, Sakao Y. 474P Effects of smoking habit in NSCLC with KRAS mutation in pathological stage I. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv532.58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
96
|
Ackermann M, Albert A, Baldini L, Ballet J, Barbiellini G, Barbieri C, Bastieri D, Bellazzini R, Bissaldi E, Bonino R, Bottacini E, Brandt TJ, Bregeon J, Bruel P, Buehler R, Caliandro GA, Cameron RA, Caraveo PA, Cecchi C, Charles E, Chekhtman A, Cheung CC, Chiang J, Chiaro G, Ciprini S, Cohen-Tanugi J, Cuoco A, Cutini S, D’Ammando F, Desiante FDPR, Digel SW, Di Venere L, Drell PS, Favuzzi C, Fegan SJ, Ferrara EC, Franckowiak A, Funk S, Fusco P, Gargano F, Gasparrini D, Giglietto N, Giordano F, Godfrey G, Grenier IA, Grondin MH, Grove JE, Guillemot L, Guiriec S, Hagiwara K, Harding AK, Hays E, Hewitt JW, Hill AB, Horan D, Johnson TJ, Knödlseder J, Kuss M, Larsson S, Latronico L, Lemoine-Goumard M, Li J, Li L, Longo F, Loparco F, Lovellette MN, Lubrano P, Maldera S, Manfreda A, Marshall F, Martin P, Mayer M, Mazziotta MN, Michelson PF, Mirabal N, Mizuno T, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Naletto G, Nuss E, Ohsugi T, Orienti M, Orlando E, Paneque D, Pesce-Rollins M, Piron F, Pivato G, Porter TA, Rainò S, Rando R, Razzano M, Reimer A, Reimer O, Reposeur T, Romani RW, Parkinson PMS, Schulz A, Sgrò C, Siskind EJ, Smith DA, Spada F, Spandre G, Spinelli P, Suson DJ, Takahashi H, Thayer JB, Thompson DJ, Tibaldo L, Torres DF, Uchiyama Y, Vianello G, Wood KS, Wood M, Zampieri L. An extremely bright gamma-ray pulsar in the Large Magellanic Cloud. Science 2015; 350:801-5. [DOI: 10.1126/science.aac7400] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
97
|
Miyatani F, Kuriyama N, Watanabe I, Nomura R, Nakano K, Matsui D, Ozaki E, Koyama T, Nishigaki M, Yamamoto T, Mizuno T, Tamura A, Akazawa K, Takada A, Takeda K, Yamada K, Nakagawa M, Ihara M, Kanamura N, Friedland RP, Watanabe Y. Relationship between Cnm-positive Streptococcus mutans and cerebral microbleeds in humans. Oral Dis 2015. [PMID: 26205098 DOI: 10.1111/odi.12360] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Cerebral hemorrhage has been shown to occur in animals experimentally infected with Streptococcus mutans carrying the collagen-binding Cnm gene. However, the relationship between cerebral microbleeds and oral hygiene, with a focus on Cnm gene-positive S. mutans infection, remains unclear. MATERIAL AND METHODS One hundred and thirty-nine subjects participated. The presence or absence of Cnm-positive S. mutans and its collagen-binding activity were investigated using saliva samples, and relationship with cerebral microbleeds detected on MRI investigated, including clinical information and oral parameters. RESULTS Fifty-one subjects were identified as Cnm-positive S. mutans carriers (36.7%), with cerebral microbleeds being detected in 43 (30.9%). A significantly larger number of subjects carried Cnm-positive S. mutans in the cerebral microbleeds (+) group. S. mutans with Cnm collagen-binding ability was detected in 39 (28.1%) of all subjects, and the adjusted odds ratio for cerebral microbleeds in the Cnm-positive group was 14.4. Regarding the presence of cerebral microbleeds, no significant differences were noted in the number of remaining teeth, dental caries, or in classic arteriosclerosis risk factors. CONCLUSIONS The occurrence of cerebral microbleeds was higher in subjects carrying Cnm-positive S. mutans, indicating that the presence of Cnm-positive S. mutans increases cerebral microbleeds, and is an independent risk for the development of cerebrovascular disorders.
Collapse
|
98
|
Ackermann M, Ajello M, Atwood WB, Baldini L, Ballet J, Barbiellini G, Bastieri D, Gonzalez JB, Bellazzini R, Bissaldi E, Blandford RD, Bloom ED, Bonino R, Bottacini E, Brandt TJ, Bregeon J, Britto RJ, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Caragiulo M, Caraveo PA, Carpenter B, Casandjian JM, Cavazzuti E, Cecchi C, Charles E, Chekhtman A, Cheung CC, Chiang J, Chiaro G, Ciprini S, Claus R, Cohen-Tanugi J, Cominsky LR, Conrad J, Cutini S, D’Abrusco R, D’Ammando F, Angelis AD, Desiante R, Digel SW, Venere LD, Drell PS, Favuzzi C, Fegan SJ, Ferrara EC, Finke J, Focke WB, Franckowiak A, Fuhrmann L, Fukazawa Y, Furniss AK, Fusco P, Gargano F, Gasparrini D, Giglietto N, Giommi P, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Grove JE, Guiriec S, Hewitt JW, Hill AB, Horan D, Itoh R, Jóhannesson G, Johnson AS, Johnson WN, Kataoka J, Kawano T, Krauss F, Kuss M, Mura GL, Larsson S, Latronico L, Leto C, Li J, Li L, Longo F, Loparco F, Lott B, Lovellette MN, Lubrano P, Madejski GM, Mayer M, Mazziotta MN, McEnery JE, Michelson PF, Mizuno T, Moiseev AA, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nuss E, Ohno M, Ohsugi T, Ojha R, Omodei N, Orienti M, Orlando E, Paggi A, Paneque D, Perkins JS, Pesce-Rollins M, Piron F, Pivato G, Porter TA, Rainò S, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Romani RW, Salvetti D, Schaal M, Schinzel FK, Schulz A, Sgrò C, Siskind EJ, Sokolovsky KV, Spada F, Spandre G, Spinelli P, Stawarz L, Suson DJ, Takahashi H, Takahashi T, Tanaka Y, Thayer JG, Thayer JB, Tibaldo L, Torres DF, Torresi E, Tosti G, Troja E, Uchiyama Y, Vianello G, Winer BL, Wood KS, Zimmer S. THE THIRD CATALOG OF ACTIVE GALACTIC NUCLEI DETECTED BY THEFERMILARGE AREA TELESCOPE. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/0004-637x/810/1/14] [Citation(s) in RCA: 424] [Impact Index Per Article: 47.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
99
|
Clark CJ, Pletsch HJ, Wu J, Guillemot L, Ackermann M, Allen B, Angelis AD, Aulbert C, Baldini L, Ballet J, Barbiellini G, Bastieri D, Bellazzini R, Bissaldi E, Bock O, Bonino R, Bottacini E, Brandt TJ, Bregeon J, Bruel P, Buson S, Caliandro GA, Cameron RA, Caragiulo M, Caraveo PA, Cecchi C, Champion DJ, Charles E, Chekhtman A, Chiang J, Chiaro G, Ciprini S, Claus R, Cohen-Tanugi J, Cuéllar A, Cutini S, D’Ammando F, Desiante R, Drell PS, Eggenstein HB, Favuzzi C, Fehrmann H, Ferrara EC, Focke WB, Franckowiak A, Fusco P, Gargano F, Gasparrini D, Giglietto N, Giordano F, Glanzman T, Godfrey G, Grenier IA, Grove JE, Guiriec S, Harding AK, Hays E, Hewitt JW, Hill AB, Horan D, Hou X, Jogler T, Johnson AS, Jóhannesson G, Kramer M, Krauss F, Kuss M, Laffon H, Larsson S, Latronico L, Li J, Li L, Longo F, Loparco F, Lovellette MN, Lubrano P, Machenschalk B, Manfreda A, Marelli M, Mayer M, Mazziotta MN, Michelson PF, Mizuno T, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nuss E, Ohsugi T, Orienti M, Orlando E, Palma FD, Paneque D, Pesce-Rollins M, Piron F, Pivato G, Rainò S, Rando R, Razzano M, Reimer A, Parkinson PMS, Schaal M, Schulz A, Sgrò C, Siskind EJ, Spada F, Spandre G, Spinelli P, Suson DJ, Takahashi H, Thayer JB, Tibaldo L, Torne P, Torres DF, Tosti G, Troja E, Vianello G, Wood KS, Wood M, Yassine M. PSR J1906+0722: AN ELUSIVE GAMMA-RAY PULSAR. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/2041-8205/809/1/l2] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
100
|
Drlica-Wagner A, Albert A, Bechtol K, Wood M, Strigari L, Sánchez-Conde M, Baldini L, Essig R, Cohen-Tanugi J, Anderson B, Bellazzini R, Bloom ED, Caputo R, Cecchi C, Charles E, Chiang J, Angelis AD, Funk S, Fusco P, Gargano F, Giglietto N, Giordano F, Guiriec S, Gustafsson M, Kuss M, Loparco F, Lubrano P, Mirabal N, Mizuno T, Morselli A, Ohsugi T, Orlando E, Persic M, Rainò S, Sehgal N, Spada F, Suson DJ, Zaharijas G, Zimmer S, Abbott T, Allam S, Balbinot E, Bauer AH, Benoit-Lévy A, Bernstein RA, Bernstein GM, Bertin E, Brooks D, Buckley-Geer E, Burke DL, Rosell AC, Castander FJ, Covarrubias R, D’Andrea CB, Costa LND, DePoy DL, Desai S, Diehl HT, Cunha CE, Eifler TF, Estrada J, Evrard AE, Neto AF, Fernandez E, Finley DA, Flaugher B, Frieman J, Gaztanaga E, Gerdes D, Gruen D, Gruendl RA, Gutierrez G, Honscheid K, Jain B, James D, Jeltema T, Kent S, Kron R, Kuehn K, Kuropatkin N, Lahav O, Li TS, Luque E, Maia MAG, Makler M, March M, Marshall J, Martini P, Merritt KW, Miller C, Miquel R, Mohr J, Neilsen E, Nord B, Ogando R, Peoples J, Petravick D, Pieres A, Plazas AA, Queiroz A, Romer AK, Roodman A, Rykoff ES, Sako M, Sanchez E, Santiago B, Scarpine V, Schubnell M, Sevilla I, Smith RC, Soares-Santos M, Sobreira F, Suchyta E, Swanson MEC, Tarle G, Thaler J, Thomas D, Tucker D, Walker AR, Wechsler RH, Wester W, Williams P, Yanny B, Zuntz J. SEARCH FOR GAMMA-RAY EMISSION FROM DES DWARF SPHEROIDAL GALAXY CANDIDATES WITH
FERMI
-LAT DATA. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/2041-8205/809/1/l4] [Citation(s) in RCA: 119] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|